Loading
Retlirafusp alfa is Hengrui's PD-L1 and TGF-beta bifunctional antibody, in phase 3 trials with chemotherapy in gastric cancer after the Western class leader bintrafusp alfa failed.
SHR-1701 combines PD-L1 blockade with a TGF-beta trap in a single molecule. Hengrui and Suncadia are running phase 3 trials with capecitabine and oxaliplatin (CAPOX) in first-line advanced gastric and gastro-oesophageal junction cancer, and further studies in cervical and other cancers, after Merck KGaA's bintrafusp alfa was discontinued in 2023 when its lung and biliary trials failed.
One arm blocks PD-L1 while the fused receptor domain soaks up TGF-beta in the tumour, attacking two immunosuppressive signals at once; the class was pioneered by bintrafusp alfa. Connects to PD-L1.
1.One arm of Retlirafusp alfa binds PD-L1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Retlirafusp alfa" OR ABSTRACT:"Retlirafusp alfa" OR TITLE:"SHR-1701" OR ABSTRACT:"SHR-1701") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Retlirafusp alfa, not a curated reading list.
Shares Bispecific antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Bispecific antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors and the tag pipeline.